Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 250,889,200
  • Shares Outstanding, K 2,529,635
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • EBIT $ 14,160 M
  • EBITDA $ 18,032 M
  • 60-Month Beta 0.40
  • Price/Sales 4.20
  • Price/Cash Flow 32.83
  • Price/Book 5.68

Options Overview Details

View History
  • Implied Volatility 24.75% ( +0.96%)
  • Historical Volatility 18.89%
  • IV Percentile 89%
  • IV Rank 63.43%
  • IV High 30.32% on 10/28/24
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 0.59
  • Today's Volume 28,308
  • Volume Avg (30-Day) 38,247
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 405,003
  • Open Int (30-Day) 403,827

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.85
  • Number of Estimates 7
  • High Estimate 2.13
  • Low Estimate 1.63
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +6,066.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
94.48 +4.97%
on 11/15/24
107.36 -7.62%
on 10/23/24
-7.46 (-7.00%)
since 10/22/24
3-Month
94.48 +4.97%
on 11/15/24
120.30 -17.56%
on 09/06/24
-17.37 (-14.90%)
since 08/22/24
52-Week
94.48 +4.97%
on 11/15/24
134.63 -26.33%
on 06/25/24
-2.50 (-2.46%)
since 11/22/23

Most Recent Stories

More News
Top Analyst Reports for Broadcom, Merck & Qualcomm

Thursday, November 21, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc....

SHOP : 106.96 (+0.45%)
MMC : 227.82 (+1.52%)
AVGO : 164.23 (+0.18%)
FI : 221.56 (+1.91%)
QCOM : 156.79 (+0.86%)
MRK : 99.18 (-0.68%)
2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

AZN : 65.63 (+2.13%)
MRK : 99.18 (-0.68%)
LLY : 748.01 (-0.25%)
MRNA : 41.11 (+7.48%)
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist

Every company faces challenges. Sometimes, those issues are deeply damaging to a corporation's investment thesis. Other times, though, that's not the case, and the price drop represents a great buying...

MRK : 99.18 (-0.68%)
PFE : 25.65 (+2.07%)
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...

BAYRY : 5.1500 (+1.18%)
AZN : 65.63 (+2.13%)
JNJ : 155.17 (-0.21%)
MRK : 99.18 (-0.68%)
ABBV : 176.95 (+3.04%)
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?

Stocks in these "safe" sectors are selling off as investors gravitate toward growth.

MO : 56.73 (+1.25%)
VHT : 265.83 (+0.17%)
KO : 63.92 (+0.25%)
MRK : 99.18 (-0.68%)
JNJ : 155.17 (-0.21%)
UNH : 590.87 (-1.11%)
COMP : 6.83 (+1.49%)
COST : 964.01 (+0.87%)
VDC : 220.23 (+1.08%)
PG : 176.28 (+2.04%)
LLY : 748.01 (-0.25%)
VPU : 176.05 (-0.38%)
3 Stocks Poised for a Breakout

All 3 stocks are high on my watchlist.

MRK : 99.18 (-0.68%)
RBLX : 49.38 (+0.06%)
UBER : 71.51 (+2.69%)
MarketBeat Week in Review – 11/4 - 11/8

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

NVDA : 141.95 (-3.22%)
SMMT : 19.00 (+3.15%)
MRK : 99.18 (-0.68%)
ALT : 8.68 (+3.27%)
ENVX : 9.43 (+3.63%)
CCL : 24.90 (-1.78%)
COIN : 304.64 (+3.19%)
BMY : 58.87 (+1.10%)
FSLR : 186.05 (+2.25%)
SOUN : 8.25 (+18.19%)
QCOM : 156.79 (+0.86%)
INTC : 24.50 (+0.25%)
Canada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement

/CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR®...

MRK : 99.18 (-0.68%)
2 Hot Biopharma Stocks to Buy and Hold for 5 Years

If you're patient, these businesses have a lot of promising projects in the works.

SMMT : 19.00 (+3.15%)
MRK : 99.18 (-0.68%)
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.

These stocks have seen better days but investors shouldn't count them out in the long run.

DG : 74.93 (+1.37%)
MRK : 99.18 (-0.68%)
NKE : 77.40 (+3.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 103.86
2nd Resistance Point 102.82
1st Resistance Point 101.00
Last Price 99.18
1st Support Level 98.14
2nd Support Level 97.11
3rd Support Level 95.29

See More

52-Week High 134.63
Fibonacci 61.8% 119.29
Fibonacci 50% 114.56
Fibonacci 38.2% 109.82
Last Price 99.18
52-Week Low 94.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar